Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients
- PMID: 19597704
- DOI: 10.1007/s10549-009-0461-7
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients
Abstract
Biocharacterization of circulating tumor cells (CTCs) in the peripheral blood of advanced breast cancer (ABC) patients may represent a real-time tumor biopsy. We assessed HER2 status on CTCs from blood samples of ABC patients. CTCs were separated and stained using the CellSearch System((R)). HER2 status was assessed by immunofluorescence and, when technically feasible, by fluorescence in situ hybridization. Blood samples were obtained from 66 ABC patients. Forty patients had a positive CTC sample (61%) and of these, 15 (37%) had HER2 + CTCs. We found non-concordant results in 32% of cases: 29% (8/28) of HER2-negative primary tumors had HER2-positive CTCs and 42% (5/12) of HER2-positive primary tumors had HER2-negative CTCs (k = 0.278). Our study suggests that a subset of patients with HER2-negative primary tumors develops HER2-positive CTCs during disease progression.
Similar articles
-
HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.Clin Cancer Res. 2006 Mar 15;12(6):1715-20. doi: 10.1158/1078-0432.CCR-05-2087. Clin Cancer Res. 2006. PMID: 16551854
-
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.Breast Cancer Res Treat. 2010 Nov;124(2):403-12. doi: 10.1007/s10549-010-1163-x. Epub 2010 Sep 22. Breast Cancer Res Treat. 2010. PMID: 20859679 Clinical Trial.
-
Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.Breast Cancer Res Treat. 2009 Oct;117(3):525-34. doi: 10.1007/s10549-008-0239-3. Epub 2008 Nov 19. Breast Cancer Res Treat. 2009. PMID: 19016323
-
HER2-positive DTCs/CTCs in breast cancer.Recent Results Cancer Res. 2012;195:203-15. doi: 10.1007/978-3-642-28160-0_19. Recent Results Cancer Res. 2012. PMID: 22527508 Review.
-
Change in HER2 status during breast tumor progression.Cancer Biomark. 2012-2013;12(6):251-5. doi: 10.3233/CBM-130313. Cancer Biomark. 2012. PMID: 23735945 Review.
Cited by
-
Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker.BMC Cancer. 2013 Apr 23;13:202. doi: 10.1186/1471-2407-13-202. BMC Cancer. 2013. PMID: 23617715 Free PMC article.
-
Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level.Br J Cancer. 2012 Feb 28;106(5):939-46. doi: 10.1038/bjc.2012.12. Epub 2012 Jan 26. Br J Cancer. 2012. PMID: 22281663 Free PMC article.
-
Genomic Instability in Circulating Tumor Cells.Cancers (Basel). 2020 Oct 16;12(10):3001. doi: 10.3390/cancers12103001. Cancers (Basel). 2020. PMID: 33081135 Free PMC article. Review.
-
Circulating tumour cells and cell-free DNA as tools for managing breast cancer.Nat Rev Clin Oncol. 2013 Jul;10(7):377-89. doi: 10.1038/nrclinonc.2013.80. Epub 2013 May 28. Nat Rev Clin Oncol. 2013. PMID: 23712187 Review.
-
An Immune-Magnetophoretic Device for the Selective and Precise Enrichment of Circulating Tumor Cells from Whole Blood.Micromachines (Basel). 2020 May 30;11(6):560. doi: 10.3390/mi11060560. Micromachines (Basel). 2020. PMID: 32486306 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous